Pinetree Capital

Pinetree Therapeutics is a preclinical-stage biotechnology company specializing in next-generation targeted protein degraders (TPD) to combat drug resistance in oncology and infectious diseases. The company's proprietary AbReptor platform designs multispecific antibody-based degraders that target membrane-bound and extracellular proteins, offering a novel mechanism of action compared to traditional inhibitors or intracellular degraders like PROTACs. Pinetree gained significant industry attention in 2024 through an exclusive option and license agreement with AstraZeneca for its lead EGFR-targeted protein degrader. Headquartered in Cambridge, Massachusetts, the company is advancing a pipeline of candidates focused on overcoming tyrosine kinase inhibitor (TKI) resistance in solid tumors.